Kimberly-Clark is laying down $40bn to buy Kenvue in a massive deal that has puzzled some investors, as the maker of Tylenol struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.
Shares of Kimberly-Clark…
Kimberly-Clark to buy Tylenol maker Kenvue for $40bn | Business and Economy News
